Aurélien Marabelle
Inserm(FR)Inserm(FR)Université Paris-Saclay(FR)Institut Gustave Roussy(FR)Assistance Publique – Hôpitaux de Paris(FR)Centre de recherche en Epidémiologie et Santé des Populations(FR)Laboratoire d'études sur les monothéismes(FR)Bicêtre Hospital(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Cancer Genomics and Diagnostics, Immune Cell Function and Interaction
Most-Cited Works
- → Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study(2019)2,869 cited
- → Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study(2020)2,424 cited
- → Immune-related adverse events with immune checkpoint blockade: a comprehensive review(2016)2,094 cited
- → Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy(2016)1,344 cited
- → A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study(2018)1,203 cited
- → Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1